Olivier Tillement
Overview
Explore the profile of Olivier Tillement including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
154
Citations
2284
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramirez M, Bou-Gharios J, Freis B, Draussin J, Cheignon C, Charbonniere L, et al.
Nanoscale
. 2025 Feb;
17(9):5021-5032.
PMID: 39903198
Developing and synthesizing nano-objects capable of enabling early targeted diagnosis and ensuring effective tumor treatment represents a significant challenge in the theranostic field. Among various nanoparticles (NPs), iron oxide nanoparticles...
2.
Salazar Ariza J, Lux F, Da Cruz-Boisson F, Resende de Azevedo J, Vera R, Tillement O, et al.
Carbohydr Polym
. 2024 Nov;
347:122670.
PMID: 39486926
In this study, a chitosan derivative with strong iron (III) chelating capabilities was developed by grafting the Deferoxamine (DFO) chelator to achieve a substitution degree of 3.8 ± 0.2 %....
3.
Dhaini B, Arnoux P, Daouk J, Lux F, Tillement O, Hagege A, et al.
Pharmaceuticals (Basel)
. 2024 Aug;
17(8).
PMID: 39204138
Photodynamic therapy is an accepted therapy cancer treatment. Its advantages encourage researchers to delve deeper. The use of nanoparticles in PDT has several advantages including the passive targeting of cancer...
4.
Howard J, David L, Lux F, Tillement O
J Hazard Mater
. 2024 Aug;
478:135361.
PMID: 39116748
The long-term effects of low-level, chronic exposure to lead and cadmium through ingestion are often overlooked, despite the urgency surrounding the clinical onset and worsening of certain pathologies caused by...
5.
Chargari C, Maury P, Texier M, Genestie C, Morice P, Bockel S, et al.
ACS Nano
. 2024 Jun;
18(26):16516-16529.
PMID: 38912600
Activated guided irradiation by X-ray (AGuIX) nanoparticles are gadolinium-based agents that have the dual benefit of mimicking the effects of a magnetic resonance imaging (MRI) contrast agent used in a...
6.
Detappe A, Kunjachan S, Sancey L, Motto-Ros V, Biancur D, Drane P, et al.
J Control Release
. 2024 Apr;
370:891.
PMID: 38653589
No abstract available.
7.
Durand A, Borisova T, Lux F, Howard J, Tillement A, Kuznietsova H, et al.
PLoS One
. 2024 Apr;
19(4):e0292414.
PMID: 38568898
To mitigate the risk of radioactive isotope dissemination, the development of preventative and curative measures is of particular interest. For mass treatment, the developed solution must be easily administered, preferably...
8.
Mathieu C, Ghosh S, Draussin J, Gasser A, Jacquot G, Banerjee M, et al.
Adv Healthc Mater
. 2024 Mar;
13(15):e2304250.
PMID: 38444191
Nanoparticle (NP) surface functionalization with proteins, including monoclonal antibodies (mAbs), mAb fragments, and various peptides, has emerged as a promising strategy to enhance tumor targeting specificity and immune cell interaction....
9.
Carmes L, Bort G, Lux F, Seban L, Rocchi P, Muradova Z, et al.
Nanoscale
. 2023 Dec;
16(5):2347-2360.
PMID: 38113032
This article presents bioconjugates combining nanoparticles (AGuIX) with nanobodies (VHH) targeting Programmed Death-Ligand 1 (PD-L1, A12 VHH) and Cluster of Differentiation 47 (CD47, A4 VHH) for active tumor targeting. AGuIX...
10.
Grea T, Jacquot G, Durand A, Mathieu C, Gasser A, Zhu C, et al.
Adv Mater
. 2023 Dec;
36(13):e2308738.
PMID: 38105299
Subcutaneous (SC) administration of monoclonal antibodies (mAbs) is a proven strategy for improving therapeutic outcomes and patient compliance. The current FDA-/EMA-approved enzymatic approach, utilizing recombinant human hyaluronidase (rHuPH20) to enhance...